Abera Bioscience AB (NGM:ABERA)
Sweden · Delayed Price · Currency is SEK 7.50
-0.30 (-3.85%)
At close: Aug 8, 2025
Abera Bioscience AB Company Description
Abera Bioscience AB, a platform and vaccine development company, research, design, and develops vaccines and immunotherapies based on its proprietary vaccine delivery platform in Sweden and internationally.
The company’s development platform named BERA, uses for the display of antigens at the surface of outer membrane vesicles derived from genetically optimized gram-negative bacteria.
Its lead vaccine candidate is a universal pneumococcal vaccine based on the platform BERA. The company also develops projects in immuno-oncology, Chlamydia, ETEC, Covid-19, and Tuberculosis.
Abera Bioscience AB was incorporated in 2012 and is based in Uppsala, Sweden.
Abera Bioscience AB
| Country | Sweden |
| Founded | 2012 |
| Industry | Biological Products, Except Diagnostic Substances |
| Employees | 5 |
| CEO | Maria Alriksson |
Contact Details
Address: Dragarbrunnsgatan 45 Uppsala, 753 720 Sweden | |
| Website | aberabio.com |
Stock Details
| Ticker Symbol | ABERA |
| Exchange | Nordic Growth Market |
| Fiscal Year | January - December |
| Reporting Currency | SEK |
| SIC Code | 2836 |
Key Executives
| Name | Position |
|---|---|
| Maria Alriksson | Chief Executive Officer |